|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:activeDuring
|
paliperidone
|
|
gptkbp:administrativeDivision
|
once daily
monthly injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availableIn
|
generic medication
|
|
gptkbp:brand
|
gptkb:Invega_Sustenna
gptkb:Invega_Trinza
|
|
gptkbp:chemicalFormula
|
C23H27ClN2O3S
|
|
gptkbp:clinicalTrials
|
Phase III
acute treatment
maintenance treatment
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to paliperidone
|
|
gptkbp:dosageForm
|
tablet
suspension
|
|
gptkbp:drugInterdiction
|
CYP3A4 inducers
CYP2D6 inhibitors
|
|
gptkbp:formFactor
|
oral tablet
extended-release tablet
|
|
gptkbp:gestationPeriod
|
C
|
|
gptkbp:hasPopulation
|
adults
adolescents
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Invega
|
|
gptkbp:is_used_in
|
metabolic syndrome
diabetes risk
tardive dyskinesia
|
|
gptkbp:lastProduced
|
2006
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketedAs
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:numberOfStudents
|
23 hours
|
|
gptkbp:nutritionalValue
|
liver
|
|
gptkbp:operates_in
|
N05AX13
|
|
gptkbp:researchAreas
|
mental health
neuroscience
psychiatry
|
|
gptkbp:route
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
anxiety
fatigue
nausea
vomiting
drowsiness
insomnia
constipation
dry mouth
weight gain
increased heart rate
|
|
gptkbp:usedFor
|
treatment of schizoaffective disorder
treatment of schizophrenia
|